Madrigal’s strategy of pursuing combination therapies while the market remains in its infancy could intrinsically link its ...

ThermoFisher expects revenue growth in the 3-6% range for 2026 and 2027, and a growth rate of 7% or more in 2028 and beyond.

GSK touted recent deals as source of fresh revenues amid patent expiries and an AI-driven boost to drug discovery.

Pfizer is gearing up for a consumer-driven obesity drug market, drawing parallels to the demand surge it experienced with the ...

The Billion Cell Atlas, backed by Eli Lilly, MSD and AstraZeneca, maps mechanisms to support informed drug discovery and ...

At the 44 th Annual J.P. Morgan Healthcare Conference, Sanofi’s growth and projection for 2026 up until the end of the decade ...

Sanofi has doubled down on R&D in a bid to brace for lost revenue from Dupixent's looming patent expiry.

In 2026, clinical trial teams market uncertainty and identify high-impact areas for AI adoption to remain competitive.

Tremfya and Icotide are touted as key growth drivers in J&J’s strongly performing innovative medicines business.

Novartis has significantly strengthened its neuroscience pipeline over recent years, topped by the $12bn acquisition of ...

J&J bolstered their pipeline with new deals in 2025. Michael Vi via Shutterstock.com. CEO Joaquin Duato presented a strong ...

Elevidys’ sales missed Q4 analyst estimates, though Sarepta’s CEO Douglas Ingram is confident of a more stable 2026 for the ...